Neurofibromatosis clinical trials at UCSD
1 in progress, 0 open to eligible people
Showing trials for
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Sorry, in progress, not accepting new patients
This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease in tumor volume reduction by 12 courses.
San Diego, California and other locations